
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Reporting on the outbreak of severe acute respiratory syndrome (SARS) is shooting at a moving target; what follows can only be a snapshot of how things looked at the end of May, when this issue of Contemporary Pediatrics went to press.






